IRFMN Silini A, Ghilar<strong>di</strong> C, Figini S, Sangalli F, Fruscio R, Dahse R, Pedley RB, Giavazzi R, Bani MR Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment Cell Mol Life Sci Dec1, 2011 E-pub Mosconi P, Taricco M, Bergamini M, Bosisio Fazzi L, Colombo Cinzia, Patrucco V, Corti M, Giobbe D, Guerreschi M, Magnarella M R, Sallemi G Family burden of severe brain injury: The Italian experience with families and volunteer associations Patient 2011 4 : 55-65 Cinquini M, Banzi R, Liberati A, Moschetti I, Pecoraro V, Tagliabue L, Moja L Speed of updating online evidence based point of care summaries: prospective cohort analysis BMJ 2011 343 : d5856 Fuso L, Evangelista S, Pagano E, Piovano E, Perotto S, Mazzola S, Bertoldo E, La Porta M R, Rosmino C, Furbatto G, Abate S, Di Costanzo G, Trossarelli G, Baù M G, Carnino F, Gambaro G, Piantanida P, Alabiso O, Galletto L, Zavallone L, Rossi A, Barbero M, Tessa M, Katsaros D, Danese S, Brignolo P, Gorzegno G, Grillo R, Apolone G, Ciccone G Variation in gynecological oncology follow-up practice: attributable to cancer centers or to patient characteristics A Piedmont Regional Oncology Network Study Tumori 2011 97 : 551-558 Greco M T, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G, CPOR SG Investigators Epidemiology and pattern of care of breakthrough cancer pain in a longitu<strong>di</strong>nal sample of cancer patients: results from the Cancer Pain Outcome Research Study Group Clin J Pain 2011 27 : 9-18 Rivera R F, Mircoli L, Bonforte G, Torri V, Monteforte M, Stella A, Genovesi S Dipyridamole stress echocar<strong>di</strong>ography in <strong>di</strong>agnosis and prognosis of hemo<strong>di</strong>alysis patients with asymptomatic coronary <strong>di</strong>sease Hemo<strong>di</strong>al Int 2011 15 : 468-476 Ganzinelli M, Mariani P, Cattaneo D, Fossati R, Fruscio R, Corso S, Ricci F, Broggini M, Damia G Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations Eur J Cancer 2011 47 : 1086-1094 Sulaiman G M, Al Sammarrae K W, Ad'hiah A H, Zucchetti M, Frapolli R, Bello E, Erba E, D'Incalci M, Bagnati R Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials Food Chem Toxicol 2011 49 : 2415-2421 Colombo V, Lupi M, Falcetta F, Forestieri D, D'Incalci M, Ubezio P Chemotherapeutic activity of silymarin combined with doxorubicin or paclitaxel in sensitive and multidrug-resistant colon cancer cells Cancer Chemother Pharmacol 2011 67 : 369-379 Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, Mantovani S, Marinou K, Papetti L, Monteforte M, Torri V, Paris L, Bazzoni G, Lunetta C, Corbo M, Mora G, Bendotti C, Bonetto V Amyotrophic lateral sclerosis multiprotein biomarkers in peripheral blood mononuclear cells PLoS One 2011 6 : e25545 Knudsen K A, Brunelli C, Kaasa S, Apolone G, Corli O, Montanari M, Fainsinger R, Aass N, Fayers P, Caraceni A, Klepstad P, European Palliative Care Research Collaborative (EPCRC), European Pharmacogenetic Study (EPOS) Which variables are associated with pain intensity and treatment response in advanced cancer patients Implications for a future classification system for cancer pain Eur J Pain 2011 15 : 320-327 34 RAPPORTO ATTIVITA’ 2011
IRFMN Manzoni C, Colombo L, Bigini P, Diana V, Cagnotto A, Messa M, Lupi M, Bonetto V, Pignataro M, Airol<strong>di</strong> C, Sironi E, Williams A, Salmona M The molecular assembly of Amyloid Aβ controls its neurotoxicity and bin<strong>di</strong>ng to cellular proteins PLoS One 2011 6 : e24909 Pronzato P, Mustacchi G, De Matteis A, Di Costanzo F, Rulli E, Floriani I, Cazzaniga M E, NORA Study Group Biological characteristics and me<strong>di</strong>cal treatment of breast cancer in young women. A featured population: Results from the NORA study International Journal Breast Cancer 2011 Kaasa S, Apolone G, Klepstad P, Loge J H, Hjermstad M J, Corli O, Strasser F, Heiskanen T, Costantini M, Zagonel V, Gronvold M, Fainsinger R, Jensen M P, Farrar J, McQuay H, Rothrock N E, Cleary J, Sepulveda C, Deguines C, Caraceni A Expert conference on cancer pain assessment and classification—the need for international consensus: working proposals on international standards BMJ Supportive & Palliative Care 2011 1 : 281-287 Gori S, Greco M T, Catania C, Colombo C, Apolone G, Zagonel V, AIOM Group A new informed consent form model for cancer patients: Preliminary results of a prospective study by the Italian Association of Me<strong>di</strong>cal Oncology (AIOM) Patient Educ Couns 2011 E-pub Garassino M C, Marabese M, Rusconi P, Rulli E, Farina G, Scanni A, Broggini M Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer Ann Oncol 2011 22 : 235-237 Bello E, Colella G, Scarlato V, Oliva P, Berndt A, Valbusa G, Serra S, D'Incalci M, Cavalletti E, Giavazzi R, Damia G, Camboni G E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models Cancer Res 2011 71 : 1396-1405 Marchini S, Cavalieri D, Fruscio R, Calura E, Garavaglia D, Fuso Nerini I, Mangioni C, Cattoretti G, Clivio L, Beltrame L, Katsaros D, Scarampi L, Menato G, Perego P, Chiorino G, Buda A, Romual<strong>di</strong> C, D'Incalci M Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections Lancet Oncol. 2011 Mar;12(3):273-85 Galfrascoli E, Piva S, Cinquini M, Rossi A, La Verde N, Bramati A, Moretti A, Manazza A, Damia G, Torri V, Muserra G, Farina G, Garassino M C, ORION Collaborative Group Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis Dig Liver Dis 2011 43 : 286-294 Casciani E, Masselli G, Di Nardo G, Polettini E, Bertini L, Oliva S, Floriani I, Cucchiara S, Gual<strong>di</strong> G MR enterography versus capsule endoscopy in pae<strong>di</strong>atric patients with suspected Crohn's <strong>di</strong>sease Eur Ra<strong>di</strong>ol 2011 21 : 823-831 Garassino M C, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghi<strong>di</strong>ni A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis Lung Cancer 2011 72 : 378-383 Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E, Ubezio P, Broggini M Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates Cancer Res 2011 E-pub 35 RAPPORTO ATTIVITA’ 2011
- Page 1 and 2: IRFMN PREFAZIONE RAPPORTI ATTIVITA
- Page 3 and 4: IRFMN PREFAZIONE Questo rapporto ha
- Page 5 and 6: IRFMN Istituto di Ricerche Farmacol
- Page 7 and 8: IRFMN DIPARTIMENTO DI ONCOLOGIA PER
- Page 9 and 10: IRFMN CURRICULA VITAE Maurizio D'In
- Page 11 and 12: IRFMN Principali pubblicazioni •
- Page 13 and 14: IRFMN • Sartore-Bianchi A, Fieuws
- Page 15 and 16: IRFMN controllati in oncologia; rev
- Page 17 and 18: IRFMN Paclitaxel plus platinum-base
- Page 19 and 20: IRFMN human plasma of patients part
- Page 21 and 22: IRFMN L’utilizzo di piccole molec
- Page 23 and 24: IRFMN dell’endometrio. Uno studio
- Page 25 and 26: IRFMN European Association for Pall
- Page 27 and 28: IRFMN Comitato Etico Fondazione CNA
- Page 29 and 30: IRFMN Tavola rotonda: Convegno Aggi
- Page 31 and 32: IRFMN “Working with patients’ a
- Page 33: IRFMN GISCAD(Gruppo Italiano Studi
- Page 37 and 38: IRFMN Zecchini S, Bombardelli L, De
- Page 39 and 40: IRFMN Mandalà M, Clerici M, Corrad
- Page 41 and 42: IRFMN sono meno sensibili a trabect
- Page 43 and 44: IRFMN farmaci singolarmente, costit
- Page 45 and 46: IRFMN Laboratorio di Farmacologia M
- Page 47 and 48: IRFMN nel processo metastatico. In
- Page 49 and 50: IRFMN Laboratorio di Biologia e Ter
- Page 51 and 52: IRFMN Da qui l'esigenza di una prof
- Page 53 and 54: IRFMN E’ in corso un altro protoc
- Page 55 and 56: IRFMN efficacia alla pratica clinic
- Page 57 and 58: IRFMN Il Comitato Tecnico Scientifi
- Page 59 and 60: IRFMN Sclerosi Multipla AISM e la T
- Page 61 and 62: IRFMN DIPARTIMENTO AMBIENTE E SALUT
- Page 63 and 64: IRFMN Emilio Benfenati, Capo del La
- Page 65 and 66: IRFMN Principali pubblicazioni: 1.
- Page 67 and 68: IRFMN chemicals within a Global Arc
- Page 69 and 70: IRFMN COLLABORAZIONI NAZIONALI AMA
- Page 71 and 72: IRFMN Interuniversitaeres Forchungi
- Page 73 and 74: IRFMN 6° Conferenza Sicurezza Prod
- Page 75 and 76: IRFMN Comune di Gorla Maggiore (VA)
- Page 77 and 78: IRFMN Baderna D, Maggioni S, Borian
- Page 79 and 80: IRFMN Bonati M, Severino F, Bagnati
- Page 81 and 82: IRFMN strutturale di proteine e pep
- Page 83 and 84: IRFMN sostanze odorigene che, tutte
- Page 85 and 86:
IRFMN DIPARTIMENTO DI NEUROSCIENZE
- Page 87 and 88:
IRFMN CURRICULA VITAE Gianluigi For
- Page 89 and 90:
IRFMN periodo di un anno in Olanda
- Page 91 and 92:
IRFMN Barbara D’Avanzo si è laur
- Page 93 and 94:
IRFMN • Calcagno E, Guzzetti S, C
- Page 95 and 96:
IRFMN - Rizzi M, Caccia S, Guiso G,
- Page 97 and 98:
IRFMN • Marcon J, Gagliardi B, No
- Page 99 and 100:
IRFMN L’azione della doxiciclina,
- Page 101 and 102:
IRFMN Esiste una correlazione diret
- Page 103 and 104:
IRFMN Assessorato alla Salute, Comu
- Page 105 and 106:
IRFMN Società INFORMA Unione Nazio
- Page 107 and 108:
IRFMN Unit of Molecular Genetics, C
- Page 109 and 110:
IRFMN Journal of Biological Chemist
- Page 111 and 112:
IRFMN Working Group on Epilepsy del
- Page 113 and 114:
IRFMN absence epilepsy at the onset
- Page 115 and 116:
IRFMN Carli M, Calcagno E, Mainini
- Page 117 and 118:
IRFMN Ghio L, Natta W, Barbato A, M
- Page 119 and 120:
IRFMN hospital stay, and in-hospita
- Page 121 and 122:
IRFMN SELEZIONE PUBBLICAZIONI DIVUL
- Page 123 and 124:
IRFMN laboratorio si sono sviluppat
- Page 125 and 126:
IRFMN prima del completamento del r
- Page 127 and 128:
IRFMN Laboratorio di Morte Neuronal
- Page 129 and 130:
IRFMN Laboratorio di Neurologia Spe
- Page 131 and 132:
IRFMN (2000-2009). Per capire quali
- Page 133 and 134:
IRFMN spostamento e di zigzagamento
- Page 135 and 136:
IRFMN Prosegue lo studio per valuta
- Page 137 and 138:
IRFMN notevoli vantaggi rispetto a
- Page 139 and 140:
IRFMN Ricerca di agenti farmacologi
- Page 141 and 142:
IRFMN intraospedaliera. Con l’obi
- Page 143 and 144:
IRFMN In particolare, i pazienti co
- Page 145 and 146:
IRFMN Lo studio valuta il profilo e
- Page 147 and 148:
IRFMN DIPARTIMENTO DI RICERCA CARDI
- Page 149 and 150:
IRFMN • The FUTURA/OASIS-8 Trial
- Page 151 and 152:
IRFMN Principali pubblicazioni •
- Page 153 and 154:
IRFMN dal 2001 dal 1997 dal 1995 da
- Page 155 and 156:
IRFMN Enrico Bjørn Nicolis ha freq
- Page 157 and 158:
IRFMN Il C4D Genetic Consortium, di
- Page 159 and 160:
IRFMN ATTIVITA' DI REVISIONE Americ
- Page 161 and 162:
IRFMN 30/11/11, Istituto di Ricerch
- Page 163 and 164:
IRFMN - La defibrillazione: i defib
- Page 165 and 166:
IRFMN Burba I, Colombo GI, Staszews
- Page 167 and 168:
IRFMN Humphries SE, Nyberg F, Cusi
- Page 169 and 170:
IRFMN Ristagno G, Pellis T, Lucange
- Page 171 and 172:
IRFMN 1 nella forma attiva, portava
- Page 173 and 174:
IRFMN T cardiaca (metodo ad alta se
- Page 175 and 176:
IRFMN centri clinici Italiani) e i
- Page 177 and 178:
IRFMN metabolismo lipidico e nella
- Page 179 and 180:
IRFMN Laboratorio di Ricerca in Med
- Page 181 and 182:
IRFMN Tuttavia, svariati fattori qu
- Page 183 and 184:
IRFMN come la patologia cardiovasco
- Page 185 and 186:
IRFMN DIPARTIMENTO DI BIOCHIMICA E
- Page 187 and 188:
IRFMN Valentina Bonetto si è laure
- Page 189 and 190:
IRFMN • Terao M, Kurosaki M, Barz
- Page 191 and 192:
IRFMN ATTIVITA' DEL DIPARTIMENTO Il
- Page 193 and 194:
IRFMN Istituto Oncologico Europeo,
- Page 195 and 196:
IRFMN PRESENZA IN COMITATI EDITORIA
- Page 197 and 198:
IRFMN Ministero dell'Istruzione, Un
- Page 199 and 200:
IRFMN Characterization and crystall
- Page 201 and 202:
IRFMN determinano l’azione citoto
- Page 203 and 204:
IRFMN elettroencefalografiche (in c
- Page 205 and 206:
IRFMN In questo settore, l’attivi
- Page 207 and 208:
IRFMN nuovi possibili meccanismi mo
- Page 209 and 210:
IRFMN malattie neurologiche. Purtro
- Page 211 and 212:
IRFMN DIPARTIMENTO DI EPIDEMIOLOGIA
- Page 213 and 214:
IRFMN del Laboratorio di Epidemiolo
- Page 215 and 216:
IRFMN • Naldi L, Chatenoud L, Bel
- Page 217 and 218:
IRFMN Un pattern alimentare basato
- Page 219 and 220:
IRFMN Nello studio INHANCE, un alto
- Page 221 and 222:
IRFMN COLLABORAZIONI NAZIONALI ASL
- Page 223 and 224:
IRFMN Registre Vaudois des Tumeurs,
- Page 225 and 226:
IRFMN ORGANIZZAZIONE DI EVENTI Meet
- Page 227 and 228:
IRFMN Convegno. Problemi vecchi e n
- Page 229 and 230:
IRFMN Medicina e Chirurgia. Titolo
- Page 231 and 232:
IRFMN Bertuccio P, Levi L, Lucchini
- Page 233 and 234:
IRFMN within the International Head
- Page 235 and 236:
IRFMN Polesel J, Talamini R, Montel
- Page 237 and 238:
IRFMN più basso del pattern caratt
- Page 239 and 240:
IRFMN 1,26 per l’indice di massa
- Page 241 and 242:
IRFMN Consumo di alcool e tumore de
- Page 243 and 244:
IRFMN faringe). Alti livelli di rPA
- Page 245 and 246:
IRFMN cardiovascolari (OR=2,87), me
- Page 247 and 248:
IRFMN Consenso dell’estensione de
- Page 249 and 250:
IRFMN tumore ha continuato a diminu
- Page 251 and 252:
IRFMN maggiore del peso corporeo re
- Page 253 and 254:
IRFMN applicazioni web 2.0 esistent
- Page 255 and 256:
IRFMN DIPARTIMENTO DI SALUTE PUBBLI
- Page 257 and 258:
IRFMN • Garattini L, Gritti S, De
- Page 259 and 260:
IRFMN consentono la formalizzazione
- Page 261 and 262:
IRFMN Laboratorio di Epidemiologia
- Page 263 and 264:
IRFMN PRESENZA IN COMMISSIONI NAZIO
- Page 265 and 266:
IRFMN Convegno: 22nd ESPNIC Medical
- Page 267 and 268:
IRFMN EFFICACIA DEL BECLOMETASONE V
- Page 269 and 270:
IRFMN Koleva D, Cortelazzo S, Toldo
- Page 271 and 272:
IRFMN Laboratorio per la Salute Mat
- Page 273 and 274:
IRFMN territorio, seppur in modo et
- Page 275 and 276:
IRFMN Il modello diagnostico sull
- Page 277 and 278:
IRFMN inoltre osservata una correla
- Page 279 and 280:
IRFMN Il progetto TINN, Treat Infec
- Page 281 and 282:
IRFMN Una sorveglianza della letter
- Page 283 and 284:
IRFMN pre-sessione (incontro a port
- Page 285 and 286:
IRFMN LABORATORIO POLITICHE REGOLAT
- Page 287 and 288:
IRFMN Valutazione di protocolli di
- Page 289 and 290:
IRFMN PRESENZA IN COMMISSIONI NAZIO
- Page 291 and 292:
IRFMN Raccolta di informazioni sui
- Page 293 and 294:
IRFMN CENTRO DI INGEGNERIA INFORMAT
- Page 295 and 296:
IRFMN Trial VALPROATO Trial THEOR
- Page 297 and 298:
IRFMN CENTRO CATULLO E DANIELA BORG
- Page 299 and 300:
IRFMN LA BIBLIOTECA PERSONALE Capo
- Page 301 and 302:
IRFMN EVENTI E CORSI Corso “La ri
- Page 303 and 304:
IRFMN Centro Anna Maria Astori Berg
- Page 305 and 306:
IRFMN DIPARTIMENTO DI MEDICINA MOLE
- Page 307 and 308:
IRFMN CURRICULA VITAE Ariela Benign
- Page 309 and 310:
IRFMN − Caprioli J, Remuzzi G, No
- Page 311 and 312:
IRFMN Sistiana Aiello si è laureat
- Page 313 and 314:
IRFMN studio della patogenesi della
- Page 315 and 316:
IRFMN malattie umane, per studiare
- Page 317 and 318:
IRFMN Medical University of Innsbru
- Page 319 and 320:
IRFMN Fondazione Compagnia di San P
- Page 321 and 322:
IRFMN Alla ricerca dei fattori coin
- Page 323 and 324:
IRFMN esprimono il marker di cellul
- Page 325 and 326:
IRFMN pre-trattati con rATG. Se que
- Page 327 and 328:
IRFMN vettore plasmidico contenente
- Page 329 and 330:
IRFMN L’ultrastruttura dei pori d
- Page 331 and 332:
IRFMN DIPARTIMENTO DI BIOINGEGNERIA
- Page 333 and 334:
IRFMN 2. Macconi D, Sangalli F, Bon
- Page 335 and 336:
IRFMN 9. Antiga L, Wasserman B, Ste
- Page 337 and 338:
IRFMN COLLABORAZIONI NAZIONALI Dipa
- Page 339 and 340:
IRFMN Seminario: "Ricostruzione tri
- Page 341 and 342:
IRFMN 4. Bode A, Caroli A, Huberts
- Page 343 and 344:
IRFMN del tessuto molle circostante
- Page 345 and 346:
IRFMN l’impiego di farmaci che ri
- Page 347 and 348:
IRFMN sulla parete laterale dell'ar
- Page 349 and 350:
IRFMN aumentano il rischio di inval
- Page 351 and 352:
IRFMN Centro di Ricerche Cliniche p
- Page 353 and 354:
IRFMN DIPARTIMENTO DI MEDICINA RENA
- Page 355 and 356:
IRFMN Aree di interesse: dal 1995
- Page 357 and 358:
IRFMN • Perico N, Antiga L, Carol
- Page 359 and 360:
IRFMN Aree di interesse: prevenzion
- Page 361 and 362:
IRFMN Mario Negri, Bergamo) e il Di
- Page 363 and 364:
IRFMN - Università degli Studi, Fi
- Page 365 and 366:
IRFMN American Journal of Transplan
- Page 367 and 368:
IRFMN CONTRIBUTI E CONTRATTI AIFA (
- Page 369 and 370:
IRFMN diabetes patients with microa
- Page 371 and 372:
IRFMN Studio clinico Delapril and M
- Page 373 and 374:
IRFMN CKD-Epi sovrastimava e la aMD
- Page 375 and 376:
IRFMN potenzialmente fatale. Infatt
- Page 377 and 378:
IRFMN effetto potrebbe determinare
- Page 379 and 380:
IRFMN Questi dati hanno costituito
- Page 381 and 382:
IRFMN delle malattie cardiovascolar
- Page 383 and 384:
IRFMN Complessivamente le malattie
- Page 385 and 386:
IRFMN numero paragonabile a quello
- Page 387 and 388:
IRFMN di cellule immunitarie sarann
- Page 389 and 390:
IRFMN DOCUMENTAZIONE E RICERCA SULL
- Page 391 and 392:
IRFMN 3. Castelletti F, Donadelli R
- Page 393 and 394:
IRFMN Nel 2000 la Commissione Europ
- Page 395 and 396:
IRFMN Corso: Come diagnosticare e t
- Page 397 and 398:
IRFMN occlusione trombotica dei pic
- Page 399 and 400:
IRFMN Centro di Coordinamento. I ra
- Page 401 and 402:
IRFMN COORDINAMENTO RAPPORTI INTERN
- Page 403 and 404:
IRFMN A.O. Ospedali Riuniti, Bergam
- Page 405 and 406:
IRFMN http://www.europlanproject.eu
- Page 407 and 408:
IRFMN Centro Ricerche Trapianti Chi
- Page 409 and 410:
IRFMN L’ATTIVITA’ DIDATTICA Res
- Page 411 and 412:
IRFMN ORGANIGRAMMA Unità organizza
- Page 413 and 414:
IRFMN Prof. Silvio Garattini Silvio
- Page 415 and 416:
IRFMN Prof. Giuseppe Remuzzi Giusep
- Page 417 and 418:
IRFMN Mario Negri Milano Direzione
- Page 419 and 420:
IRFMN Centro Anna Maria Astori Berg
- Page 421:
IRFMN Centro Aldo e Cele Daccò Ran